Novocure’s FDA-approved TTF therapy device, Optune, has shown modest results in extending life spans for glioblastoma ...

Developed by Jersey, US-based Novocure, Optune beams so-called Tumour Treating Fields (TTFs) through the scalp and into brain tumours where they disrupt cell division. Because of the shifting ...

Marketed by Novocure, the Optune device consists of four inter-connected patches that cover the skull and deliver the company’s patented Tumour Treating Fields (TTFields). These electrical ...

Scientists at Phoenix Children's Research Institute at the University of Arizona College of Medicine — Phoenix have achieved ...

The tumor was shrinking. Next I tried therapy administered with an Optune, an advanced technology that uses a net of ...

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor ...

The 46-year-old described a treatment called Optune as a "real beacon of hope" and believes it would give her the chance to "buy some time". But health chiefs in the UK believe the treatment is ...

The 46-year-old previously launched a campaign for a treatment called Optune to be funded by the NHS and asked for help to access it. But the mother-of-two's requests for help have been refused.

Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Novocure has launched Optune, its first TTFields delivery system, for the treatment of glioblastoma multiforme and potentially other solid tumor indications. For over 100 years, surgery ...

Check out our weekly list of new fundraisers from Lend A Hand Up, a nonprofit crowdfunding site supporting families in Cass, ...